BetterLife Pharma Inc.
BetterLife Pharma Inc.
Your view on BETRF
Overview
What the company does, where it operates, and who runs it.
About BetterLife Pharma Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ahmad Doroudian
- Headquarters
- 1275 West 6th Avenue, Vancouver, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ahmad Doroudian
- Headquarters
- 1275 West 6th Avenue, Vancouver, BC, CA
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally.
It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections.
The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity.
It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution.
The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BetterLife Pharma Inc., and the rating behind it. BETRF last traded at $0.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BetterLife Pharma Inc.. Starting points for BetterLife Pharma Inc.: EPS -$0.01, beta 0.54 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BetterLife Pharma Inc.. BetterLife Pharma Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BetterLife Pharma Inc.. Trailing twelve-month EPS for BetterLife Pharma Inc. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BetterLife Pharma Inc.. BetterLife Pharma Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BetterLife Pharma Inc. valued side by side against its closest peers. BetterLife Pharma Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BetterLife Pharma Inc., and how their positions are changing. At a $6.4M market value, institutional positions materially move BetterLife Pharma Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BetterLife Pharma Inc. executives and directors. Shares of BetterLife Pharma Inc. have traded between $0.03 and $0.09 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BetterLife Pharma Inc.. BetterLife Pharma Inc. is a $6.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BetterLife Pharma Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BetterLife Pharma Inc.. Coverage tracks BetterLife Pharma Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.